{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T09:49:26Z","timestamp":1648979366042},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.2023","type":"journal-article","created":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T01:11:49Z","timestamp":1412125909000},"page":"2241-2243","source":"Crossref","is-referenced-by-count":2,"title":["Late Hematological Improvement of Myelodysplastic Syndrome Following Treatment with 5-Azacitidine Therapy"],"prefix":"10.2169","volume":"53","author":[{"given":"Kensuke","family":"Takaoka","sequence":"first","affiliation":[{"name":"Department of Hematology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hangaishi","sequence":"additional","affiliation":[{"name":"Department of Hematology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Morioka","sequence":"additional","affiliation":[{"name":"Department of Hematology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Kida","sequence":"additional","affiliation":[{"name":"Department of Hematology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 31: 727-736, 2007."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 113: 6296-6303, 2009.","DOI":"10.1182\/blood-2008-09-038935"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088, 1997.","DOI":"10.1182\/blood.V89.6.2079"},{"key":"4","unstructured":"4. Itzykson R, Thépot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117: 403-411, 2011."},{"key":"5","unstructured":"5. Mahesh KKN. Molecules of the Millennium-Azacitidine: A novel drug for myelodysplastic syndrome. Indian J Pharmacol 37: 414-415, 2005."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tsao CF, Dalal J, Peters C, Gonzalez C, Kearns GL. Azacitidine pharmacokinetics in an adolescent patient with renal compromise. J Pediatr Hematol Oncol 29: 330-333, 2007.","DOI":"10.1097\/MPH.0b013e31805d8f21"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Uchida T, Ogawa Y, Kobayashi Y, et al. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci 102: 1680-1686, 2011.","DOI":"10.1111\/j.1349-7006.2011.01993.x"},{"key":"8","unstructured":"8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232, 2009."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 117: 2697-2702, 2011.","DOI":"10.1002\/cncr.25774"},{"key":"10","unstructured":"10. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110: 4385-4395, 2007."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108: 419-425, 2006.","DOI":"10.1182\/blood-2005-10-4149"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Maywald O, Buchheidt D, Bergmann J, et al. Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection-case report and review of the literature. Ann Hematol 83: 189-194, 2004.","DOI":"10.1007\/s00277-003-0741-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Valentiny C, Lisa Pleyer M, Steurer M, Willenbacher W. Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia. Wien Klin Wochenschr 125: 50-53, 2013.","DOI":"10.1007\/s00508-012-0319-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29: 516-523, 2011.","DOI":"10.1200\/JCO.2010.31.0854"},{"key":"15","unstructured":"15. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429-2440, 2002."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/19\/53_53.2023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:51:45Z","timestamp":1621446705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/19\/53_53.2023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":15,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.2023","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}